A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)

NCT01717287 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infection

Interventions

DRUG: Raltegravir Film-coated Tablet
DRUG: Raltegravir Chewable Tablet
DRUG: Other Anti-Retroviral Therapy

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]